GlassScriptPhysician profile
Drew J Stoken
NPI 1336113588
$2,458.17
in general payments reported to CMS, 2019-2025
25 companies · $16.95 in 2025
The $16.95 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2020: $186 · 2021: $192 · 2022: $967 · 2023: $499 · 2024: $239 · 2025: $16.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $737 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $736.89 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Notal Vision, INC. | $509.33 | 2022 | |
| Alcon Vision LLC | $316.45 | 2019-2023 | Argos, Hydrus Microstent |
| Regeneron Healthcare Solutions, INC. | $237.39 | 2020-2024 | Eylea Hd, Eylea |
| Novartis Pharmaceuticals Corporation | $225.54 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $190.54 | 2019-2025 | Cequa, Xelpros |
| Abbvie INC. | $168.32 | 2022-2024 | Alphagan P, Lumigan, Ozurdex |
| Bausch & Lomb Americas INC. | $149.22 | 2022-2024 | Ic-8 Apthera Iol, Envista Mx60 Iol, Xiidra |
| Allergan, INC. | $105.58 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $70.75 | 2022 | |
| Genentech USA, INC. | $67.07 | 2019-2023 | Vabysmo |
| Johnson & Johnson Surgical Vision, INC. | $53.52 | 2019-2021 | |
| Glaukos Corporation | $51.99 | 2021-2022 | |
| Aerie Pharmaceuticals, INC. | $45.51 | 2019-2020 | |
| Oyster Point Pharma, INC. | $43.28 | 2022-2023 | Tyrvaya |
| Apellis Pharmaceuticals, INC. | $41.32 | 2022-2023 | Syfovre |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $34.91 | 2019 | |
| Rxsight INC | $24.73 | 2022 | |
| Thea Pharma INC. | $21.54 | 2023 | |
| Astellas Pharma US INC | $18.18 | 2023 | |
| Kala Pharmaceuticals, INC. | $15.44 | 2019 | |
| Omeros Corporation | $15.11 | 2020 | |
| Carl Zeiss Meditec USA, INC. | $13.67 | 2021 | |
| Ivantis, INC | $13.62 | 2019 | |
| Eyevance Pharmaceuticals LLC | $12.68 | 2022 | |
| Sight Sciences, INC. | $12.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Drew Stoken listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.